These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29282764)

  • 21. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Instrumental variable with competing risk model.
    Zheng C; Dai R; Hari PN; Zhang MJ
    Stat Med; 2017 Apr; 36(8):1240-1255. PubMed ID: 28064466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of restricted mean time lost under competing risks data.
    Lyu J; Hou Y; Chen Z
    BMC Med Res Methodol; 2020 Jul; 20(1):197. PubMed ID: 32711456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation.
    Tanase T
    Pharm Stat; 2020 Mar; 19(2):126-136. PubMed ID: 32067336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models.
    Lô SN; Ma J; Manuguerra M; Moreno-Betancur M; Scolyer RA; Thompson JF
    Stat Methods Med Res; 2022 May; 31(5):978-994. PubMed ID: 35037794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
    Rauch G; Beyersmann J
    Stat Med; 2013 Sep; 32(21):3595-608. PubMed ID: 23553898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semiparametric competing risks regression under interval censoring using the R package intccr.
    Park J; Bakoyannis G; Yiannoutsos CT
    Comput Methods Programs Biomed; 2019 May; 173():167-176. PubMed ID: 31046992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size formula for proportional hazards modelling of competing risks.
    Latouche A; Porcher R; Chevret S
    Stat Med; 2004 Nov; 23(21):3263-74. PubMed ID: 15490425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dealing with competing risks: testing covariates and calculating sample size.
    Pintilie M
    Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frailty modeling for clustered competing risks data with missing cause of failure.
    Lee M; Ha ID; Lee Y
    Stat Methods Med Res; 2017 Feb; 26(1):356-373. PubMed ID: 25125452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time.
    Akazawa K; Nakamura T; Moriguchi S; Shimada M; Nose Y
    Comput Methods Programs Biomed; 1991 Jul; 35(3):203-12. PubMed ID: 1935013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute risk from double nested case-control designs: cause-specific proportional hazards models with and without augmented estimating equations.
    Lee M; Gail MH
    Biometrics; 2024 Jul; 80(3):. PubMed ID: 38994640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Planning and analyzing clinical trials with competing risks: Recommendations for choosing appropriate statistical methodology.
    Poythress JC; Lee MY; Young J
    Pharm Stat; 2020 Jan; 19(1):4-21. PubMed ID: 31625290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculation for multi-arm parallel design with restricted mean survival time.
    Chen Y; Lam KF; Xu J
    Stat Methods Med Res; 2024 Jan; 33(1):130-147. PubMed ID: 38093411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semiparametric regression and risk prediction with competing risks data under missing cause of failure.
    Bakoyannis G; Zhang Y; Yiannoutsos CT
    Lifetime Data Anal; 2020 Oct; 26(4):659-684. PubMed ID: 31982977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution.
    Katsahian S; Resche-Rigon M; Chevret S; Porcher R
    Stat Med; 2006 Dec; 25(24):4267-78. PubMed ID: 16960919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.